OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in HIV and AIDS is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Updates on bone health in people living with HIV: global impact, prediction tools, and treatment	98
Future options for long-acting HIV treatment and prevention	70
Recent advances on anti-HIV chimeric antigen receptor-T-cell treatment to provide sustained HIV remission	50
The sounds of silencing: dynamic epigenetic control of HIV latency	37
HIV-associated tuberculosis in infants, children, and adolescents younger than 15 years: an update on the epidemiology, diagnosis, prevention, and treatment	31
Impact of early antiretroviral therapy, early life immunity and immune sex differences on HIV disease and posttreatment control in children	28
Harnessing natural killer cells to target HIV-1 persistence	26
Statins for primary cardiovascular disease prevention among people with HIV: emergent directions	26
Persistent elite controllers as the key model to identify permanent HIV remission	25
Loneliness and social isolation in people with HIV	23
Editorial introduction	23
Editorial introduction	22
A behavioral economics approach to enhancing HIV preexposure and postexposure prophylaxis implementation	22
Editorial introduction	22
Fc-mediated immunological mechanisms in HIV infection: a better understanding for improved therapeutic approaches	19
Challenges towards an AIDS-free generation in Africa and Asia	19
Development of screening assays for use of broadly neutralizing antibodies in people with HIV	19
New latency-promoting agents for a block-and-lock functional cure strategy	18
Current insight into HIV-1 persistence from single-cell transcriptome profiling in acutely treated cohorts of infection	18
Defining multimorbidity in people with HIV – what matters most?	17
Balancing polypharmacy and comorbidity management: cardiovascular health	17
The origins of new SARS-COV-2 variants in immunocompromised individuals	17
Role of follicular homing natural killer cells in HIV infection	14
Viral and immune predictors of HIV posttreatment control	14
Mpox and the impact on people with HIV	13

Editorial introduction	13
The multifaceted nature of HIV tissue reservoirs	12
New vector and vaccine platforms: mRNA, DNA, viral vectors	12
Aging of adult lifetime survivors with perinatal HIV	12
Impact of coronavirus disease 2019 on co-morbidities in HIV	12
Single-cell multiomic understanding of HIV-1 reservoir at epigenetic, transcriptional, and protein levels	11
Metabolic dysfunction-associated steatotic liver disease in people with HIV	11
Obesity among women with HIV	11
Hepatitis co-infection in paediatric HIV: progressing treatment and prevention	11
Frailty in people with HIV: a geriatric syndrome approach to aging with HIV	11
Renal adverse drug reactions	11
Editorial: New drugs for HIV: quo vadis?	10
Broadly neutralizing antibodies for HIV treatment and cure approaches	10
Host factors predisposing to kidney disease in people with HIV	10
Editorial introduction	10
Beyond criminalization: reconsidering HIV criminalization in an era of reform	10
The severity of COVID-19 across the spectrum of HIV	10
HIV and cardiovascular disease: the role of inflammation	10
Gender and sex considerations in HIV and bone health	10
Strategies to target the central nervous system HIV reservoir	9
Persistent HIV-1 transcription during ART: time to reassess its significance?	9
HIV drug resistance in various body compartments	9
CD8+ T-cell responses in HIV controllers: potential implications for novel HIV remission strategies	9
Causes and outcomes of hepatic fibrosis in persons living with HIV	9
Innovative models of care supporting people aging with HIV	8
Editorial: Is it time to implement injectable antiretroviral treatments globally?	8
The pathogenesis of obesity in people living with HIV	7
Editorial introduction	7
Adolescents and young adults with HIV and unsuppressed viral load: where do we go from here?	7
Editorial introductions	7
Guiding HIV-1 vaccine development with preclinical nonhuman primate research	7
Vaccinal effect of HIV-1 antibody therapy: dream or reality?	7
HIV-1 subtypes and latent reservoirs	7
Editorial introductions	7
Progress with induction of HIV broadly neutralizing antibodies in the Duke Consortia for HIV/AIDS Vaccine Development	6
Stem cell transplantation and allogeneic immunity: post treatment control or HIV cure?	6
Towards a molecular profile of antiretroviral therapy-free HIV remission	6
How could HIV-1 drug resistance impact preexposure prophylaxis for HIV prevention?	6
The innovative use of qualitative and mixed methods research to advance improvements along the HIV prevention and care continua	6
Role of islatravir in HIV treatment and prevention: an update	6
Whole person HIV services: a social science approach	6
Care of people aging with HIV in resource limited settings	6
HIV and comorbidities – the importance of gut inflammation and the kynurenine pathway	6
Scaling up preexposure prophylaxis to maximize HIV prevention impact	6
Human papillomavirus infection among adolescents living with HIV: a focus on prevention	5
Towards an HIV cure: one cell at a time	5
Promoting patient-centered care within HIV care settings in sub-Saharan Africa	5
Safety of oral tenofovir disoproxil - emtricitabine for HIV preexposure prophylaxis in adults	5
Editorial introductions	5
Cardiovascular disease risk in women living with HIV	5

Key population perceptions and opinions about long-acting antiretrovirals for prevention and treatment: a scoping review	5
Editorial introductions	5
It's all in the gut: the central role of the gut and microbiome in preventing disease progression in simian immunodeficiency viruses infected African nonhuman primates	4
Humanized mice for studying HIV latency and potentially its eradication	4
Age at ART initiation and proviral reservoir size in perinatal HIV-1 infection: considerations for ART-free remission	4
Zika virus: an overview update	4
Single cell analyses of the HIV reservoir in the CNS and CSF: recent insights and implications	4
Editorial introductions	4
Epidemiology of HIV drug resistance in low- and middle-income countries and WHO global strategy to monitor its emergence	4
Delivery platforms for broadly neutralizing antibodies	4
Editorial introduction	4
Cognitive impairment in persons with HIV: changing aetiologies and management strategies	4
Editorial: HIV and cardiovascular disease: recognizing and reducing disparities	4
The power of ten in HIV remission: insights from hematopoietic stem cell transplantation	4
Monocytes across life span in HIV infection: lights and shadows	4
Human models that inform antiretroviral therapy-free remission with perinatally acquired HIV infection	3
Recent data on the role of antiretroviral therapy in weight gain and obesity in persons living with HIV	3
The predictive value of macaque models of preexposure prophylaxis for HIV prevention	3
Management of pain and other palliative needs in older people with HIV	3
Using single cell technologies to understand HIV latency models	3
Immune checkpoint inhibition as a therapeutic strategy for HIV eradication: current insights and future directions	3
Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage	3
Implementation of long-acting antiretroviral therapy in low-income and middle-income countries	3
Advancing considerations of context in the evaluation and implementation of evidence-based biomedical HIV prevention interventions: a review of recent research	3
Editorial introduction	3
Pediatric immunotherapy and HIV control	3
Post-intervention control in HIV immunotherapy trials	3
The vaginal microbiome and HIV transmission dynamics	3
Hepatotoxicity of contemporary antiretroviral drugs	2
Immune signatures and biomarkers of viral control in early-treated children with HIV: insights informing intervention	2
HIV T-cell immunogen design and delivery	2
Humoral immunity in HIV-1 post-treatment controllers	2
Public health services and intersectional stigma: a social sciences perspective with implications for HIV service design and delivery	2
Lenacapavir: a first-in-class HIV-1 capsid inhibitor	2
Promises and challenges: cabotegravir for preexposure prophylaxis	2
HIV and obesity: updates in management strategies	2
Utilizing immunotherapy towards achieving a functional cure for HIV-1	2
A world of choices: preference elicitation methods for improving the delivery and uptake of HIV prevention and treatment	2
Understanding residual risk of cardiovascular disease in people with HIV	2
Stepping stones to cure in children with HIV	2
Long-acting preexposure prophylaxis in low- and middle-income countries: key considerations for implementation	2
Preventing perinatal HIV acquisition; current gaps and future perspectives	2
Long-acting preexposure prophylaxis: early data on roll-out in the United States	2
Ending the HIV epidemic for all, not just some: structural racism as a fundamental but overlooked social-structural determinant of the US HIV epidemic	2
Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development	2
The future of long-acting agents for preexposure prophylaxis	2
Pulmonary comorbidities in people with HIV− the microbiome connection	2
Editorial introductions	2
Editorial introductions	2
Transforming HIV prevention: the promise of long-acting preexposure prophylaxis in high HIV burden settings	2
Editorial introductions	2